Condition
MRSA Bacteremia
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed2
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06069206Not ApplicableCompleted
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
NCT05225558Phase 2TerminatedPrimary
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
NCT04597242Unknown
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
NCT03096405CompletedPrimary
Impact MRSA -PCR on Patient Management
Showing all 4 trials